protocolSection identificationModule nctId: NCT06380738, orgStudyIdInfo id: D0817R00074, secondaryIdInfos id: D0817R00074, type: OTHER, domain: AstraZeneca, briefTitle: Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed), acronym: PROceed, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-14, primaryCompletionDateStruct date: 2027-01-31, completionDateStruct date: 2027-01-31, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: AstraZeneca, class: INDUSTRY, collaborators name: Merck Sharp & Dohme LLC, descriptionModule briefSummary: PROceed is a multisite, prospective, observational study that describes the real-world use and clinical experience of mCRPC patients treated with the combination of olaparib and abiraterone in the mCRPC setting. Clinical outcomes will be assessed in patients who are either NHA-naive or NHA-exposed prior to initiating olaparib + abiraterone treatment, respectively. Patient demographic and clinical characteristics, as well as treatment received prior and subsequent to olaparib + abiraterone, will also be described. The study plans to enroll patients for a maximum of 2 years and follow up patients from initiation of olaparib until 1 year post last patient in., conditionsModule conditions: Metastatic Castration-resistant Prostate Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 250, type: ESTIMATED, outcomesModule primaryOutcomes measure: Time to treatment discontinuation, secondaryOutcomes measure: Time to first subsequent therapy, eligibilityModule sex: MALE, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Research Site, status: RECRUITING, city: Aschaffenburg, country: Germany, geoPoint lat: 49.97704, lon: 9.15214, locations facility: Research Site, status: RECRUITING, city: Berlin, country: Germany, geoPoint lat: 52.52437, lon: 13.41053, locations facility: Research Site, status: NOT_YET_RECRUITING, city: Berlin, country: Germany, geoPoint lat: 52.52437, lon: 13.41053, locations facility: Research Site, status: RECRUITING, city: Duisburg, country: Germany, geoPoint lat: 51.43247, lon: 6.76516, locations facility: Research Site, status: NOT_YET_RECRUITING, city: Franckfurt, country: Germany, locations facility: Research Site, status: RECRUITING, city: Halle, country: Germany, geoPoint lat: 51.48159, lon: 11.97948, locations facility: Research Site, status: RECRUITING, city: Herzogenaurach, country: Germany, geoPoint lat: 49.56798, lon: 10.88565, locations facility: Research Site, status: NOT_YET_RECRUITING, city: Leipzig, country: Germany, geoPoint lat: 51.33962, lon: 12.37129, locations facility: Research Site, status: NOT_YET_RECRUITING, city: Lueneburg, country: Germany, geoPoint lat: 53.2509, lon: 10.41409, locations facility: Research Site, status: RECRUITING, city: Muhlheim, country: Germany, geoPoint lat: 50.11667, lon: 8.83333, locations facility: Research Site, status: RECRUITING, city: Nurnberg, country: Germany, geoPoint lat: 49.45421, lon: 11.07752, locations facility: Research Site, status: RECRUITING, city: Russelsheim, country: Germany, geoPoint lat: 49.98955, lon: 8.42251, locations facility: Research Site, status: RECRUITING, city: Speyer, country: Germany, geoPoint lat: 49.32083, lon: 8.43111, locations facility: Research Site, status: RECRUITING, city: Wetzlar, country: Germany, geoPoint lat: 50.56109, lon: 8.50495, hasResults: False